The release of negative regulators of immune activation (immune checkpoints) that limit
antitumor responses has resulted in unprecedented rates of long-lasting tumor responses in …

Cancer immunotherapy can induce long lasting responses in patients with metastatic cancers
of a wide range of histologies. Broadening the clinical applicability of these treatments …

‘Immune checkpoint blockade’ for cancer describes the use of therapeutic antibodies that
disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour immune …

Therapies that target the programmed death-1 (PD-1) receptor have shown unprecedented
rates of durable clinical responses in patients with various cancer types 1 , 2 , 3 , 4 , 5 . One …

Background Approximately 75% of objective responses to anti–programmed death 1 (PD-1)
therapy in patients with melanoma are durable, lasting for years, but delayed relapses have …

Background The identification of somatic mutations in the gene encoding the serine–threonine
protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test …

Cancer immunotherapy may become a major treatment backbone in many cancers over the
next decade. There are numerous immune cell types found in cancers and many …

Background Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032)
have shown response rates of more than 50% in patients with metastatic melanoma with …

Background The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment
for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (…

Background Immune checkpoint inhibitors are effective cancer treatments, but molecular
determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies …